Becton, Dickinson And Co shares are trading higher after the company received FDA 510(k) clearance for its Alaris Infusion System.
Portfolio Pulse from Benzinga Newsdesk
Becton, Dickinson And Co has received FDA 510(k) clearance for its Alaris Infusion System, leading to a rise in its share prices.
July 24, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Becton, Dickinson And Co's stock is trading higher after the company received FDA 510(k) clearance for its Alaris Infusion System.
The FDA 510(k) clearance for Becton, Dickinson And Co's Alaris Infusion System is a positive regulatory development for the company. This clearance allows the company to market and sell the product in the US, potentially leading to increased revenues. As a result, investors are reacting positively, leading to a rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100